LAS VEGAS, NV–(Marketwired – Jun 30, 2015) – After years of exhaustive research and development, the BioAdaptives team (OTCBB: BDPT) is excited to reveal the first five products in our nationwide roll-out, taking place in the third quarter of 2015.

These high quality, cutting edge, natural nutraceutical blends use our proprietary process that enhances the effectiveness of the ingredients.

PrimiCell® – Helps you naturally produce more stem cells to enhance your body’s innate ability to strengthen and repair itself;

PrimiLive™ – The non-caffeinated energy booster that safely helps to increase focus while reducing fatigue;

PrimiTrim™ – For healthy weight management;

Equine Regen Plus™ – Increases circulating stem cells in horses, speeding recovery and increasing overall wellness;

Canine Regen™ – Stem Cell activator for dogs. Helps improve mobility, coat, focus, temperament, and more. Many dogs show dramatic results within a week.

“It’s been a long and rewarding process to develop these products,” said Barry Epling, Chairman & CEO. “We are genuinely excited about the prospects to improve the overall wellness of our customers.”

“The pet and equine market is often overlooked,” said Christopher G. Hall, President. “The potential for us is huge.”

About BioAdaptives, Inc.

BioAdaptives, Inc. is a fully reporting, public company trading on the OTC Bulletin Board under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for human and animal consumption. The company’s focus is to source high quality, unique, raw material worldwide and develop science-based products to improve health and wellness in both humans and animals. BioAdaptives, Inc. owns the rights to a proprietary method that is a non-invasive bioelectromagnetic device for improving individual ingredients, food, beverages, and wellness.

SAFE HARBOR ACT

Forward-Looking Statements: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of BioAdaptives, Inc. and its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond BioAdaptives, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in BioAdaptives, Inc.’s filings with the Securities and Exchange Commission.

Contact:

BioAdaptives, Inc.
info@bioadaptives.com
www.bioadaptives.com
888-280-0789